<DOC>
	<DOCNO>NCT00614939</DOCNO>
	<brief_summary>Saxagliptin new investigational medication develop treatment type 2 diabetes . This study design test efficacy daily saxagliptin renally impaired patient .</brief_summary>
	<brief_title>Treatment Effect Saxagliptin Compared With Placebo Patients With Type 2 Diabetes Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Diagnosed type 2 diabetes Documented history CrCl &lt; 50 ml/min within 3 month prior enrollment HbA1c ≥7.0 % ≤11.0 % Type 1 diabetes , history diabetic ketoacidosis hyposmolar nonketonic coma Previous current treatment DPPIV inhibitor and/or GLP1 mimetic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>HbA1c</keyword>
	<keyword>incretins</keyword>
	<keyword>Renal Impairment</keyword>
</DOC>